CD8A and hepatocellular carcinoma: In HCC patients treated with atezolizumab plus bevacizumab, Ki-67+PD-1+CD8+ T cells showed a positive correlation with OS in Lee et al.‘s study (n = 29) [97], whereas PD-L1+CD8+ T cells were significantly negatively correlated with treatment response in Gramantieri et al.‘s study (n = 37) [98].